Original articleA Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration: Clinical and Economic Impact
Section snippets
Methods
Institutional review board approval at Wills Eye Institute was obtained to review patient data for this retrospective, interventional, consecutive case series from 2 treating physicians (CDR and RSK) in a single clinical practice. Informed consent was not required for this deidentified review.
Baseline Characteristics
Ninety-two eyes from 92 patients met the inclusion and exclusion criteria. The mean age was 80.6 years (range, 61–94; standard deviation, 6.6), 61 were female (66.3%), and all participants were Caucasian. There were 48 right eyes (52%) and 50 pseudophakic eyes (54%). These baseline characteristics were comparable to the MARINA, ANCHOR, and PrONTO trials (Table 2). The mean duration of visual symptoms before treatment was 74.8 days (median, 30; range, 1–365). Forty-six eyes (50%) were treated
Discussion
The TER used in this study demonstrated favorable visual acuity results in patients with nAMD with significantly fewer visits and intravitreal injections compared with treatment in a fixed, monthly fashion such as in the MARINA and ANCHOR trials. Compared with the PrONTO study, there were a lower mean number of office visits and tests with a higher total annual mean number of treatments. The direct medical costs between the PrONTO and TER were similar.
Owing to the patient, physician, and
References (16)
- et al.
Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration
Ophthalmology
(2009) - et al.
Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration
Am J Ophthalmol
(2009) Ranibizumab according to need: a treatment for age-related macular degeneration
Am J Ophthalmol
(2007)- et al.
A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration
Ophthalmology
(2009) Causes and prevalence of visual impairment among adults in the United States
Arch Ophthalmol
(2004)Vision Research—A National Plan: 1999-2003
- et al.
Ranibizumab versus verteporfin for neovascular age-related macular degeneration
N Engl J Med
(2006) - et al.
Ranibizumab for neovascular age-related macular degeneration
N Engl J Med
(2006)
Cited by (271)
Antivascular endothelial growth factor agents for wet age-related macular degeneration: an IRIS registry analysis
2023, Canadian Journal of OphthalmologyThe economics of vision impairment and its leading causes: A systematic review
2022, eClinicalMedicineResults of the treatment of patients with exudative AMD during the COVID-19 pandemic
2022, Archivos de la Sociedad Espanola de OftalmologiaReal-life results in treating neovascular age-related macular degeneration with anti-VEGF therapy. Analysis of 122 patients from a single centre
2022, Archivos de la Sociedad Espanola de Oftalmologia
Manuscript no. 2009-821.
Financial Disclosure(s): The authors have made the following disclosures:
Carl D. Regillo - consultant - Genentech, Inc., Novartis Pharmaceuticals Corp., and Alcon Laboratories, Inc.
Richard S. Kaiser - consultant and lecturer - Genentech, Inc.
None of the authors received financial support from Genentech, Inc. or other commercial sources for this study.
Supported by the Heed Ophthalmic Foundation (OPG) and the Ronald G. Michels Fellowship Foundation Award (OPG).